EGFL7 and central nervous system cancer: Upon glioma implantation, these mice were treated twice a week by intraperitoneal injection of an α5β1‐inhibiting antibody or isotype control, which increased the survival of animals for about 4.5 days (Fig 5H), verifying that EGFL7 affected glioma growth dependent on integrin α5β1.